The pharmacological treatment of epilepsy in adults

The Lancet Neurology

Volumn 10, Issue 5, 2011, Pages 446-456

  Perucca, Emilio ^a,b   Tomson, Torbjörn ^c  

^a UNIVERSITY OF PAVIA   (Italy)

^b C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CLOBAZAM; ENZYME INDUCING AGENT; ESLICARBAZEPINE ACETATE; ESTROGEN; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; RUFINAMIDE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ABSENCE; AGE; ANTICONVULSANT THERAPY; ATONIC SEIZURE; BEDTIME DOSAGE; BONE DISEASE; CHOLESTEROL BLOOD LEVEL; CLEFT PALATE; CLINICAL DECISION MAKING; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONGENITAL MALFORMATION; CRANIOFACIAL SYNOSTOSIS; DROP ATTACK; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; EPILEPSY; EYE TOXICITY; FOCAL EPILEPSY; GENDER; GRAND MAL SEIZURE; HEART ATRIUM SEPTUM DEFECT; HUMAN; HYPONATREMIA; INTELLIGENCE QUOTIENT; LENNOX GASTAUT SYNDROME; MENTAL DISEASE; MONOTHERAPY; MYOCLONUS SEIZURE; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SPINA BIFIDA; SUSTAINED RELEASE FORMULATION; TERATOGENICITY; TONIC CLONIC SEIZURE; TONIC SEIZURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ADULT; ANTICONVULSANTS; EPILEPSY; HUMANS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 79954622504     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(11)70047-3     Document Type: Review

References (104)

1. Epilepsy and seizure statistics Epilepsy Foundation, (accessed Dec 31, 2010). http://www.epilepsyfoundation.org/about/statistics.cfm.
2. Hesdorffer DC, Logroscino G, Benn EKT, Katri N, Cascino G, Hauser WA Estimating risk for developing epilepsy. A population-based study in Rochester, Minnesota. Neurology 2011, 76:23-27.
3. Kale R Bringing epilepsy out of the shadows. BMJ 1997, 315:2-3.
4. Epilepsy in the WHO European region (2010) International League Against Epilepsy/International Bureau for Epilepsy/World Health Organization Global Campaign Against Epilepsy, (accessed Dec 31, 2010). http://www.ibe-epilepsy.org/downloads/EURO%20Report%20160510.pdf.
5. Tomson T, Beghi E, Sundqvist A, Johannessen SI Medical risks in epilepsy: a review with focus on physical injuries, mortality, traffic accidents and their prevention. Epilepsy Res 2004, 60:1-16.
6. Sillanpää M, Shinnar S Long-term mortality in childhood-onset epilepsy. N Engl J Med 2010, 363:2522-2529.
7. Epilepsy must become a higher priority in Europe. Lancet Neurol 2010, 9:941. The Lancet Neurology.
8. Raspall-Chaure M, Neville BG, Scott RC The medical management of the epilepsies in children: conceptual and practical considerations. Lancet Neurol 2008, 7:57-69.
9. Shorvon SD Drug treatment of epilepsy in the century of the ILAE: the first 50 years, 1909-1958. Epilepsia 2009, 50(suppl 3):69-92.
10. Perucca E, Beghi E, Dulac O, Shorvon S, Tomson T Assessing risk to benefit ratio in antiepileptic drug therapy. Epilepsy Res 2000, 41:107-139.
11. Tomson T, Nashef L, Ryvlin P Sudden unexpected death in epilepsy: current knowledge and future directions. Lancet Neurol 2008, 7:1021-1031.
12. Berg AT, Shinnar S The risk of seizure recurrence following a first unprovoked seizure: a quantitative review. Neurology 1991, 41:965-972.
13. Hauser WA, Rich SS, Lee JR, Annegers JF, Anderson VE Risk of recurrent seizures after two unprovoked seizures. N Engl J Med 1998, 338:429-434.
14. Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizure and epilepsy: definitions proposed by the International League against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005, 46:470-472.
15. Guidelines for epidemiological studies on epilepsy. Epilepsia 1993, 34:592-596. Commission on epidemiology and prognosis, International League Against Epilepsy.
16. Randomized clinical trial on the efficacy of antiepileptic drugs in reducing the risk of relapse after a first unprovoked tonic clonic seizure. Neurology 1993, 43:478-483. First Seizure Trial Group (FIRST Group).
17. Marson A, Jacoby A, Johnson A, et al. Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet 2005, 365:2007-2013.
18. Musicco M, Beghi E, Solari A, Viani F Treatment of first tonic-clonic seizure does not improve the prognosis of epilepsy. Neurology 1997, 49:991-998.
19. Leone MA, Solari A, Beghi E Treatment of the first tonic-clonic seizure does not affect long-term remission of epilepsy. Neurology 2006, 67:2227-2229. FIRST Group.
20. Jacoby A, Gamble C, Doughty J, Marson A, Chadwick D Quality of life outcomes of immediate or delayed treatment of early epilepsy and single seizures. Neurology 2007, 68:1188-1196. Medical Research Council MESS Study group.
21. Kim LG, Johnston TL, Marson AG, Chadwick DW Prediction of risk of recurrence after a single seizure and early epilepsy: further results from the MESS trial. Lancet Neurol 2006, 5:317-322. on behalf of the MRC MESS Study group.
22. Marson AG When to start antiepileptic drug treatment and with what evidence?. Epilepsia 2008, 49(suppl 9):3-6.
23. Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006, 47:1094-1120.
24. Perucca E, Tomson T Monotherapy trials with the new antiepileptic drugs: study designs, practical relevance and ethical implications. Epilepsy Res 1999, 33:247-262.
25. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs, I: treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2004, 45:401-409.
26. Clinical guideline 20 the epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care National Institute for Clinical Excellence, (accessed Jan 1, 2011). http://www.nice.org.uk/nicemedia/live/10954/29532/29532.pdf.
27. Diagnosis and management of epilepsy in adults. A national clinical guideline. updated Oct 20, 2005 Scottish Intercollegiate Guidelines Network, (accessed Jan 1, 2011). http://www.sign.ac.uk/pdf/sign70.pdf.
28. Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007, 68:402-408. Levetiracetam Monotherapy Study Group.
29. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007, 369:1000-1015. on behalf of the SANAD Study group.
30. Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007, 369:1016-1026.
31. Perucca E, V Alexandre, Tomson T Old versus new antiepileptic drugs: the SANAD study. Lancet 2007, 370:313.
32. Perucca E Introduction to the choice of antiepileptic drugs. The treatment of epilepsy 2009, 121-140. Wiley-Blackwell, Oxford, UK. S.D. Shorvon, E. Perucca, J. Engel (Eds.).
33. Harden CL, Meador KJ, Pennell PB, et al. Practice parameter update: management issues for women with epilepsy-focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes. Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and American Epilepsy Society. Epilepsia 2009, 50:1237-1246.
34. Artama M, Auvinen A, Raudaskoski T, Isojärvi I, Isojärvi J Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology 2005, 264:1874-1878.
35. Vajda FJ, Hitchcock A, Graham J, O'Brien T, Lander C, Eadie M The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Aust N Z J Obstet Gynecol 2007, 47:468-474.
36. Wide K, Winbladh B, Kallen B Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr 2004, 93:174-176.
37. Wyszynski DF, Nambisan M, Surve T, et al. Antiepileptic Drug Pregnancy Registry. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005, 64:961-965.
38. Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006, 77:193-198.
39. Veiby G, Daltveit AK, Engelsen BA, Gilhus NE Pregnancy, delivery, and outcome for the child in maternal epilepsy. Epilepsia 2009, 50:2130-2139.
40. Jentink J, Loane MA, Dolk H, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med 2010, 362:2185-2193.
41. Meador KJ, Baker GA, Browning N, et al. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009, 360:1597-1605.
42. Samren EB, van Duijn CM, Koch S, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997, 38:981-990.
43. Samren EB, van Duijn CM, Christiaens GC, Hofman A, Lindhout D Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 1999, 46:739-746.
44. Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999, 33:145-158.
45. Nicolson A, Appleton RE, Chadwick DW, Smith DF The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies. J Neurol Neurosurg Psychiatry 2004, 75:75-79.
46. Mohanraj R, Brodie MJ Outcomes of newly diagnosed idiopathic generalized epilepsy syndromes in a non-pediatric setting. Acta Neurol Scand 2007, 115:204-208.
47. Pennell PB, Peng L, Newport DJ, et al. Lamotrigine in pregnancy. Clearance, therapeutic drug monitoring and seizure frequency. Neurology 2008, 70:2130-2136.
48. Longo B, Forinash AB, Murphy JA Levetiracetam use in pregnancy. Ann Pharmacother 2009, 43:1692-1695.
49. Ohman I, Sabers A, de Flon P, Luef G, Tomson T Pharmacokinetics of topiramate during pregnancy. Epilepsy Res 2009, 87:124-129.
50. Gomer B, Wagner K, Saar J, et al. The influence of antiepileptic drugs on cognition: a comparison of levetiracetam with topiramate. Epilepsy Behav 2007, 10:486-494.
51. Hunt S, Russell A, Smithson WH, et al. Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 2008, 71:272-276.
52. Kothare SV, Valencia I, Khurana DS, Hardison H, Melvin JJ, Legido A Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. Epileptic Disord 2004, 6:267-270.
53. Brodie MJ, Elder AT, Kwan P Epilepsy in later life. Lancet Neurol 2009, 8:1019-1030.
54. Brodie MJ, Overstall PW, Giorgi L Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 1999, 37:81-87.
55. Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine and carbamazepine. Neurology 2005, 64:1868-1873.
56. Saetre E, Perucca E, Isojärvi J, Gjerstad L An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia 2007, 48:1292-1302. LAM 40089 Study Group.
57. Patsalos PN, Perucca E Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003, 2:473-481.
58. Mintzer S, Mattson RT Should enzyme-inducing antiepileptic drugs be considered first-line agents?. Epilepsia 2009, 50(suppl 8):42-50.
59. Goadsby PJ, Sprenger T Current practice and future directions in the prevention and acute management of migraine. Lancet Neurol 2010, 9:285-298.
60. Kanner A Depression and epilepsy: a review of multiple facets of their close relation. Neurol Clin 2009, 27:865-880.
61. Hesdorffer DC, Berg AT, Kanner AM An update on antiepileptic drugs and suicide: are there definitive answers yet?. Epilepsy Currents 2010, 10:137-145.
62. Spina E, Perugi G Antiepileptic drugs: indications other than epilepsy. Epileptic Disord 2004, 6:57-75.
63. Mula M, Pini S, Cassano GB The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J Clin Psychopharmacol 2007, 27:263-272.
64. Perucca E, Dulac O, Shorvon S, Tomson T Harnessing the clinical potential of antiepileptic drug therapy: dosage optimisation. CNS Drugs 2001, 15:609-621.
65. Kale R, Perucca E Revisiting phenobarbital for epilepsy. BMJ 2004, 329:1199-1200.
66. Perucca E Extended-release formulations of antiepileptic drugs: rationale and comparative value. Epilepsy Curr 2009, 9:153-157.
67. Gidal BE, Tomson T Debate: substitution of generic drugs in epilepsy: is there cause for concern?. Epilepsia 2008, 49(suppl 9):56-62.
68. Kesselheim AS, Stedman MR, Bubrick EJ, et al. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs 2010, 70:605-621.
69. Kwan P, Brodie MJ Effectiveness of first antiepileptic drug. Epilepsia 2001, 42:1255-1260.
70. Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008, 49:1239-1276.
71. Kwan P, Brodie MJ Early identification of refractory epilepsy. N Engl J Med 2000, 342:314-319.
72. Hirsch LJ, Arif H, Nahm EA, Buchsbaum R, Resor SR, Bazil CW Cross-sensitivity of skin rashes with antiepileptic drug use. Neurology 2008, 71:1527-1534.
73. Leach JP, Lauder R, Nicolson A, Smith DF Epilepsy in the UK: misdiagnosis, mistreatment, and undertreatment? The Wrexham area epilepsy project. Seizure 2005, 14:514-520.
74. Faught E, Duh MS, Weiner JR, Guérin A, Cunnington MC Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM Study. Neurology 2008, 71:1572-1578.
75. Perucca E Pharmacoresistance in epilepsy. How should it be defined?. CNS Drugs 1998, 10:171-179.
76. Schiller Y, Najjar Y Quantifying the response to antiepileptic drugs: effect of past treatment history. Neurology 2008, 70:54-65.
77. Beghi E, Gatti G, Tonini C, et al. Adjunctive therapy versus alternative monotherapy in patients with partial epilepsy failing on a single drug: a multicentre, randomised, pragmatic controlled trial. Epilepsy Res 2003, 57:1-13.
78. Kwan P, Brodie MJ Combination therapy in epilepsy: when and what to use. Drugs 2006, 66:1817-1829.
79. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010, 51:1069-1077.
80. Spencer SS, Berg AT, Vickrey BG, et al. Initial outcomes in the Multicenter Study of Epilepsy Surgery. Neurology 2003, 61:1680-1685.
81. Callaghan BC, Anand K, Hesdorffer D, Hauser WA, French JA Likelihood of seizure remission in an adult population with refractory epilepsy. Ann Neurol 2007, 62:382-389.
82. Luciano AL, Shorvon SD Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol 2007, 62:375-381.
83. Beyenburg S, Stavem K, Schmidt D Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis. Epilepsia 2010, 51:7-26.
84. Rheims S, Perucca E, Cucherat M, Ryvlin P Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis. Epilepsia 2011, 52:219-233.
85. Canevini MP, De Sarro G, Galimberti CA, et al. Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy. Epilepsia 2010, 51:797-804.
86. Patsalos PN, Perucca E Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2003, 2:347-356.
87. Deckers CL, Czuczwar SJ, Hekster YA, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 2000, 41:1364-1374.
88. Besag FM, Berry DJ, Pool F, Newbery JE, Subel B Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction?. Epilepsia 1998, 39:183-187.
89. Barcs G, Walker EB, Elger CE, et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 2000, 41:1597-1607.
90. Brodie MJ, Rosenfeld WE, Vazquez B, et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia 2009, 50:1899-1909.
91. Sake JK, Hebert D, Isojärvi J, et al. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs 2010, 24:1055-1068.
92. Brodie MJ, Yuen AW Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group. Epilepsy Res 1997, 26:423-432.
93. Wong IC, Mawer GE, Sander JW, Lhatoo SD A pharmacoepidemiologic study of factors influencing the outcome of treatment with lamotrigine in chronic epilepsy. Epilepsia 2001, 42:1354-1358.
94. Pisani F, Oteri G, Russo MF, Di Perri R, Perucca E, Richens A The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 1999, 40:1141-1146.
95. Perucca E, Kwan P Overtreatment in epilepsy: how it occurs and how it can be avoided. CNS Drugs 2005, 19:897-908.
96. Gilliam FG, Fessler AJ, Baker G, Vahle V, Carter J, Attarian H Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial. Neurology 2004, 62:23-27.
97. Uijl SG Adjustment of treatment increases quality of life in patients with epilepsy: a randomized controlled pragmatic trial. Eur J Neurol 2009, 16:1173-1177.
98. Ciechanowski P, Chaytor N, Miller J, et al. PEARLS depression treatment for individuals with epilepsy: a randomized controlled trial. Epilepsy Behav 2010, 19:225-231.
99. Specchio LM, Beghi E Should antiepileptic drugs be withdrawn in seizure-free patients?. CNS Drugs 2004, 18:201-212.
100. Jacoby A, Johnson A, Chadwick D Psychosocial outcomes of antiepileptic drug discontinuation. The Medical Research Council Antiepileptic Drug Withdrawal Study Group. Epilepsia 1992, 33:1123-1131.
101. Lossius MI, Hessen E, Mowinckel P, et al. Consequences of antiepileptic drug withdrawal: a randomized, double-blind study (Akershus study). Epilepsia 2008, 49:455-463.
102. Chadwick D, Taylor J, Johnson T Outcomes after seizure recurrence in people with well-controlled epilepsy and the factors that influence it. The MRC Antiepileptic Drug Withdrawal Group. Epilepsia 1996, 37:1043-1050.
103. Schmidt D, Löscher W Uncontrolled epilepsy following discontinuation of antiepileptic drugs in seizure-free patients: a review of current clinical experience. Acta Neurol Scand 2005, 111:291-300.
104. Sirven JI, Sperling M, Wingerchuk DM Early versus late antiepileptic drug withdrawal for people with epilepsy in remission. Cochrane Database Syst Rev 2001, 3. CD001902.